Overview

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Status:
Completed
Trial end date:
2020-08-21
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with seborrheic dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Arcutis Biotherapeutics, Inc.
Arcutis, Inc.